International Network of VENous Thromboembolism Clinical Research Networks

A A
Print screen
Search
close
Toggle menu

Fostering International VTE Research Collaboration

INVENT-VTE seeks to improve the care of patients affected by venous thromboembolism (VTE) around the world through the design, development, conduct and promotion of high-quality clinical research into the causes, prevention, diagnosis and optimal management of VTE.

99
Countries Involved
99
Funding Opportunities
99
Endorsed Studies (Active)

Endorsed Studies

Search

TILE

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

Sponsor:

Sunnybrook Health Sciences Centre

Toronto, Canada   

Current Participant(s):

Canada, France,

Status:

  • Seeking sites and collaborators

Lead Network:

CanVECTOR

VERDICT

Venous thromboembolism in renally impaired patients and direct oral anticoagulants

Sponsor:

Centre Hospitalier Universitaire de Saint Etienne

Saint Etienne, France

Current Participant(s):

Canada, France, Serbia, Spain, Switzerland,

Status:

  • Seeking sites and collaborators

Lead Network:

INNOVTE

RENOVE

REduced dose versus full-dose of direct oral anticoagulant after uNprOvoked Venous thromboEmbolism. The RENOVE open-label, randomized, controlled trial

Sponsor:

Brest University Hospital

Brest, France

Current Participant(s):

France,

Status:

  • Recruitment to stop on June 30, 2022

Lead Network:

INNOVTE

SAVER

Statins for Venous Event Reduction in Patients with Venous Thromboembolism

Sponsor:

Ottawa Hospital Research Institute

Current Participant(s):

Canada,

Status:

  • Pilot trial recruitment completed in Canada and Norway
  • Recruiting 
  • Seeking sites & collaborators 

Lead Network:

CanVECTOR

PEITHO-III

A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism

Sponsor:

Hopital Européen Georges Pompidou, Assistance Publique Hopitaux de Paris, Université Paris Descartes

Current Participant(s):

Belgium, Canada, France, Germany, Italy, Poland, Romania, Spain, The Netherlands,

Status:

  • Recruiting 
  • Seeking sites and collaborators

Lead Network:

INNOVTE

Pilot PARTUM

Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity

Sponsor:

University of Calgary

Current Participant(s):

Canada, France, Ireland, The Netherlands,

Status:

  • Recruiting
  • Seeking sites & collaborators 

Lead Network:

CanVECTOR

ADJUST-DVT

Age-adjusted d-dimer cutoff levels to rule out deep vein thrombosis

Sponsor:

University Hospital

Geneva, Switzerland

Current Participant(s):

Canada, Switzerland,

Status:

  • Recruiting 
  • Seeking sites & collaborators 

Lead Network:

INNOVTE

REDUCE

Management of recurrent venous thromboembolism during anticoagulant treatment in cancer patients - a prospective cohort study

Sponsor:

Amsterdam University Medical Center

Amsterdam, the Netherlands

Current Participant(s):

Italy, Spain, Switzerland, The Netherlands,

Status:

  • Recruiting 
  • Seeking sites & collaborators 

Lead Network:

DTN

Rhea 

Optimizing diagnosis of splanchnic vein thrombosis with MR direct thrombus imaging

Sponsor:

  • The Netherlands: Dutch Thrombosis Network  (Leiden University Medical Center, Leiden; Erasmus Medisch Centrum, Rotterdam)
  • Italy: Thrombosis Research Italian Partnership (Varese University Hospital, Varese)

Current Participant(s):

Italy, The Netherlands,

Lead Network:

DTN

COBRRA

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

Sponsor:

OHRI (Ottawa Hospital Research Institute)

Current Participant(s):

Australia & New Zealand, Canada,

Status:

  • Recruiting
  • Seeking sites & Collaborators 

Lead Network:

CanVECTOR

SAFE-SSPE

Clinical Surveillance vs. Anticoagulation For low-risk patiEnts with isolated SubSegmental Pulmonary Embolism: a multicenter randomized placebo-controlled non-inferiority trial

Sponsor:

Inselspital, Bern University Hospital, University of Bern

Current Participant(s):

Canada, Switzerland, The Netherlands,

Status:

Recruiting 

Lead Network:

DTN

MEDEA

Heavy MEnstrual bleeding in premenopausal women treated with DirEct oral Anticoagulants

Sponsor:

Amsterdam University Medical Center

Current Participant(s):

Ireland, The Netherlands,

Status:

Recruiting

Lead Network:

DTN

Determinants and Impact of the Post- Venous Thromboembolism (VTE) Syndromes

Determinants and Impact of the Post- Venous Thromboembolism (VTE) Syndromes

Sponsor:

Leiden University Medical Center, Leiden, The Netherlands.

Current Participant(s):

Canada, Ireland, The Netherlands,

Lead Network:

DTN

LEaD

Safely Ruling out Deep Vein Thrombosis in Pregnancy with the LEFt Clinical Decision Rule and D-dimer

Sponsor:

Current Participant(s):

Canada, Switzerland, The Netherlands,

Status:

  • Recruiting

Lead Network:

CanVECTOR

Real-World Use of DOACs in Children: An International Registry

Real-World Use of DOACs in Children: An International Registry

Sponsor:

  • Children’s Hospital of Philadelphia
  • University of Amsterdam

Current Participant(s):

The Netherlands, USA,

Lead Network:

VENUS

DAYS

A pilot study to assess feasibility of evaluating the safety and efficiency of a simplified diagnostic approach for deep vein thrombosis

Sponsor:

Queen’s University

Current Participant(s):

Canada, The Netherlands,

Status:

Recruitment has not started.

Lead Network:

CanVECTOR

API-CALF

Apixaban to treat calf vein thrombosis

Sponsor:

Sunnybrook Research Institute, University of Toronto

Current Participant(s):

Canada, France,

Status:

Recruitment has not started.

Lead Network:

CanVECTOR

HYDRA

Safety and efficiency of the YEARS algorithm versus computed tomography pulmonary angiography alone for suspected pulmonary embolism in patients with malignancy

Sponsor:

Leiden University Medical Center

Current Participant(s):

Belgium, France, Spain, Switzerland, The Netherlands,

Status:

  • Recruiting
  • Seeking sites & Collaborators 

Lead Network:

DTN

PREP and GO

A prospective cohort study evaluating peripartum anticoagulation management among pregnant women with VTE and its impact on patient outcomes

Sponsor:

University of Calgary

Current Participant(s):

France, Ireland, The Netherlands, USA,

Status:

  • Recruiting
  • Seeking sites & collaborators 

Lead Network:

CanVECTOR

SPECTACULAR

Comparison of 3 Diagnostic Strategies of PE: Planar V/Q Scan, CTPA, and V/Q SPECT

Sponsor:

Brest University Hospital

Brest, France

Current Participant(s):

Canada, France, Switzerland,

Status:

  • Recruiting 
  • Seeking sites & collaborators 

Lead Network:

INNOVTE

Dose-Adjusted Apixaban

A Clinical Trial of Dose-Adjusted Apixaban In CancerPatients with Thrombocytopenia and Venous Thromboembolism

Sponsor:

Beth Israel Deaconess Medical Center, USA

Current Participant(s):

The Netherlands, USA,

Lead Network:

VENUS

CONQUER-DVT Pilot

Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis

Sponsor:

Gabriele d'Annunzio University, Italy

University of Ottawa; Ottawa Hospital Research Institute, Canada

Current Participant(s):

Canada, Italy,

Status:

Recruiting 

Lead Network:

TRIP

HYPATIA

A Prospective Randomised Controlled Trial of Hydroxychloroquine Versus Placebo during Pregnancy in Women with Antiphospholipid Antibodies

Sponsor:

Rigshospitalet, Denmark (EU sites)

Guy’s and St Thomas’, UK ( UK and Canadian sites)

Current Participant(s):

Canada, Denmark, United Kingdom,

Status:

Recruiting 

Lead Network:

CanVECTOR

BAT-VTE

Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets

Sponsor:

Centre Hospitalier Universitaire de Saint Etienne, France

Current Participant(s):

Canada, France,

Status:

Recruiting 

Lead Network:

INNOVTE

PROSPECT

Sponsor:

International Pediatric Thrombosis Network

Current Participant(s):

The Netherlands,

Lead Network:

VENUS

Subscribe

* indicates required

Contact Permissions

Please select the ways you would like to hear from INVENT Network:

Contact Permissions

By clicking below to subscribe, you agree to the terms of our privacy policy.